Inovio Pharmaceuticals' GAAP loss for 9M 2021 was $196.711 million, up 37.4% from $143.137 million in the previous year. Revenue decreased 48.9% to $0.936 million from $1.831 million a year earlier.
Inovio Pharmaceuticals' GAAP loss for 9M 2021 was $196.711 million, up 37.4% from $143.137 million in the previous year. Revenue decreased 48.9% to $0.936 million from $1.831 million a year earlier. 
ir.inovio.com
English (US) 